Skip to main content
. 2023 Dec 19;14:1298815. doi: 10.3389/fimmu.2023.1298815

Figure 1.

Figure 1

Flow chart of the treatment schedule from the diagnosis of SjD and DLBCL to CAR-T cell therapy. (A) Number of circulating CAR-T cells assessed via flow cytometry from day 0 to day 90 after CAR-T cell therapy. (B) Changes in the levels of five types of cytokines from day 0 to day 90 after CAR-T cell therapy assessed using a human cytokine detection kit with flow cytometry (Qingdao Raisecare Biotechnology). (C) PET–CT images before and 28 days after CAR-T cell infusion. (D) Changes in chest CT findings before and after CAR-T cell infusion (E). The white arrow indicates the location of the retroperitoneal lesion. *: Lenalidomide was administered at a dose of 25 mg/day for 1–10 days per month during 79–89 months. #: Supportive care: intermittent transfusion of platelets and other blood products. SjD: Sjögren’s disease; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response; PD, progressive disease; PR: partial response; CAR-T, chimeric antigen receptor-T cell; ICE, ifosfamide, carboplatin, and etoposide; IL, interleukin; TNF, tumor necrosis factor; IFN-γ, interferon gamma; IVIG, intravenous immunoglobulin.